Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To present the first real-world data of patients with treatment-resistant depression (TRD) treated with esketamine through a French cohort Temporary Authorisation for Use (ATUc) programme. METHODS: In 2019, the French Health Authorities exceptionally granted the first ATUc in psychiatry for TRD patients. Clinical characteristics, safety and efficacy data were reported by physicians. The ATUc ended ∼6 months after initiation. RESULTS: = 66; median age 53.0 years; 62.1% female; 78.8% with severe major depressive episodes; resistance to a mean of 4.2 previous antidepressants) received esketamine treatment for a median of 30 days. Among 46 analysed patients, 22 (47.8%) achieved response (Montgomery-Åsberg Depression Rating Scale [MADRS] total score reduction ≥50.0%) and 17 (37.0%) achieved remission (MADRS total score of ≤12) at least once at a median of 18.5 (2.0-77.0) and 21.0 (2.0-46.0) days after initiation, respectively. By Week 4, patients had a 31.6% probability of achieving remission (Kaplan-Meier method). Sedation, somnolence, dizziness, hypertension, anxiety and dissociation were the most frequently reported (>10.0%) adverse events. No new safety signals were identified. CONCLUSIONS: Patient characteristics of this cohort demonstrate high-level treatment resistance. The safety and efficacy of esketamine in patients with TRD in real-world clinical practice were consistent with Phase 3 trials.Key pointsPatients with treatment-resistant depression (TRD) exceptionally received esketamine nasal spray ahead of its launch through a French cohort Temporary Authorisation for Use (ATUc) programme.The clinical characteristics of 66 adult patients with TRD included in this cohort demonstrated a high-level of resistance to conventional treatments at the time of treatment request prior to esketamine initiation.No new safety signals were observed with esketamine initiation during the ATUc period compared with the Phase 3 clinical trials.The safety and efficacy of esketamine in the real world remain consistent with that established in Phase 3 clinical trials.The data collected during this ATUc also provide the first real-world data on the management and practical use of esketamine in a hospital setting in France.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Real-world effectiveness data on intranasal esketamine administered over a study period of six months (n = 66) found a response rate of 47.8% and a remission rate of 37% [67].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [67]
Citations
Cites
null (2016) · Philosophy Study · doi:10.17265/2159-5313/2016.09.003 · Cited by 28,317
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
The American Psychological Association
Langfeld, H. S. (1919) · Science · doi:10.1126/science.49.1254.51 · Cited by 7,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“…of patients did not achieve remission even after two treatment steps and were considered to be experiencing treatment-resistant depression (TRD) (Rush et al. 2006), defined as failure to respond or no remission after two or more prior treatment steps with different ADs given at adequate dose…”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“Overall, the safety and tolerability profile of esketamine in this French ATUc programme was acceptable and consistent with the findings described in previous studies (Daly et al. 2019; Fedgchin et al. 2019; Popova et al. 2019; Ochs-Ross et al. 2020; Wajs et al. 2020).”
BackgroundResultInfluentialPopova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 5×
“Overall, the safety and tolerability profile of esketamine in this French ATUc programme was acceptable and consistent with the findings described in previous studies (Daly et al. 2019; Fedgchin et al. 2019; Popova et al. 2019; Ochs-Ross et al. 2020; Wajs et al. 2020).”
BackgroundResultInfluentialDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795 · cited 3×
“There were no new safety signals during the ATUc period compared with the Phase 3 clinical trial data for esketamine (Daly et al. 2019; Fedgchin et al. 2019; Popova et al. 2019; Ochs-Ross et al. 2020; Wajs et al. 2020).”
ResultFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
Research works printed but not linked: 2
- Léon C, 2018, Bull Epidémiol Hebd, 32, 637
- Thase ME, 1997, J Clin Psychiatry, 58, 23
Cited by
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Bulteau, S., Laurin, A., Pere, M., Fayet, G., Thomas-Ollivier, V., Deschamps, T., Auffray-Calvier, E., Bukowski, N., Vanelle, J.-M., Sébille, V., et al. (2022) · Brain Stimulation · doi:10.1016/j.brs.2022.05.011 · Cited by 97
Self-citationGlutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Maina, G., Adami, M., Ascione, G., Bondi, E., Berardis, D. D., Delmonte, D., Maffezzoli, S., Martinotti, G., Nivoli, A., Ottavianelli, E., et al. (2023) · Annals of General Psychiatry · doi:10.1186/s12991-023-00478-7 · Cited by 67
d’Andrea, G., Pettorruso, M., Lorenzo, G. D., Rhee, T. G., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., Nicola, M. D., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.038 · Cited by 60
Metadata
- Authors
- Samalin, L., Rothärmel, M., Mekaoui, L., Gaudré-Wattinne, E., Codet, M.-A., Bouju, S., & Sauvaget, A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Centre Hospitalier du Rouvray (FR)
- Mental and Brain Illness Clinic, Sainte-Anne Hospital, GHU Paris – Psychiatry and Neurosciences, Paris, France
- Medical Affairs, Janssen-Cilag, Issy-les-Moulineaux, France
- Janssen (France) (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Corresponding author
- Samalin, Ludovic
- Venue
- International Journal of Psychiatry in Clinical Practice
- Publisher
- Informa UK Limited
- Published
- 2022-02-17
- Volume
- 26
- Issue
- 4
- Pages
- 352-362
- ISSN
- 1365-1501 (ISSN-L)
- 1471-1788
- OpenAlex
- W4213247170
- Cited by
- 54
- References
- 40
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 17 · 2023: 14 · 2022: 3
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Psychiatry in Clinical Practice (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- Funders
- Janssen-Cilag
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, major depressive disorder, real-world data, antidepressant resistance, treatment response and remission, adverse events, dissociation, sedation, hypertension, French cohort, drug safety and efficacy, early access program
- MeSH terms
- Administration, Intranasal, Adult, Depression, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. https://app.cochat.ai/papers/10.1080/13651501.2022.2030757
- The paper
- Samalin, L., Rothärmel, M., Mekaoui, L., Gaudré-Wattinne, E., Codet, M.-A., Bouju, S., & Sauvaget, A. (2022). Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651501.2022.2030757
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.